Do analysts prefer VAXX or NXTC?

NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation & earnings, VAXX or NXTC?

NextCure is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is VAXX or NXTC more profitable?

Vaxxinity's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A NextCure N/A -186.96% -124.62%

Do analysts recommend VAXX or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 306.23%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VAXX or ERNA more profitable?

Vaxxinity's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A Ernexa Therapeutics N/A -263.74% -151.16%

Do analysts rate TNFA or VAXX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, TNFA or VAXX?

Vaxxinity is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A Vaxxinity N/A N/A -$56.93M -$0.45 N/A

Is TNFA or VAXX more profitable?

Vaxxinity's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Vaxxinity N/A N/A N/A

Do analysts recommend VAXX or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 391.40%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, VAXX or CNSP?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is VAXX or CNSP more profitable?

Vaxxinity's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A CNS Pharmaceuticals N/A -238.68% -166.30%

Which has higher earnings and valuation, ACXP or VAXX?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Vaxxinity N/A N/A -$56.93M -$0.45 N/A

Is ACXP or VAXX more profitable?

Vaxxinity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Vaxxinity N/A N/A N/A

Vaxxinity (VAXX) Competitors

$0.01 0.00 (0.00%)

As of 12:09 PM Eastern

Compare

VAXX vs. NXTC, ERNA, TNFA, CNSP, and ACXP

Should you buy Vaxxinity stock or one of its competitors? MarketBeat compares Vaxxinity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxxinity include NextCure (NXTC), Ernexa Therapeutics (ERNA), TNF Pharmaceuticals (TNFA), CNS Pharmaceuticals (CNSP), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.

How does Vaxxinity compare to NextCure?

Vaxxinity (NASDAQ:VAXX) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

NextCure is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
NextCure	Neutral

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vaxxinity has a beta of -79.23, meaning that its stock price is 8,023% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,328.57%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vaxxinity's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
NextCure	N/A	-186.96%	-124.62%

Summary

Vaxxinity beats NextCure on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to Ernexa Therapeutics?

Vaxxinity (NASDAQ:VAXX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Vaxxinity's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-263.74%	-151.16%

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 306.23%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
Ernexa Therapeutics	Neutral

Ernexa Therapeutics has higher revenue and earnings than Vaxxinity. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Ernexa Therapeutics	$580K	14.90	-$14.08M	-$26.20	N/A

Vaxxinity has a beta of -79.23, meaning that its stock price is 8,023% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the broader market.

Summary

Ernexa Therapeutics beats Vaxxinity on 7 of the 13 factors compared between the two stocks.

How does Vaxxinity compare to TNF Pharmaceuticals?

TNF Pharmaceuticals (NASDAQ:TNFA) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -79.23, suggesting that its stock price is 8,023% less volatile than the broader market.

Vaxxinity's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Vaxxinity	N/A	N/A	N/A

Vaxxinity is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, TNF Pharmaceuticals had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for TNF Pharmaceuticals and 0 mentions for Vaxxinity. TNF Pharmaceuticals' average media sentiment score of 0.95 beat Vaxxinity's score of 0.00 indicating that TNF Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
TNF Pharmaceuticals	Positive
Vaxxinity	Neutral

9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by company insiders. Comparatively, 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

TNF Pharmaceuticals beats Vaxxinity on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to CNS Pharmaceuticals?

Vaxxinity (NASDAQ:VAXX) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Vaxxinity's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

Vaxxinity has a beta of -79.23, meaning that its share price is 8,023% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market.

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CNS Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 391.40%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
CNS Pharmaceuticals	Neutral

Summary

Vaxxinity beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the broader market. Comparatively, Vaxxinity has a beta of -79.23, indicating that its share price is 8,023% less volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
Vaxxinity	Neutral

Vaxxinity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Vaxxinity	N/A	N/A	N/A

Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 2,060.28%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A

Summary

Vaxxinity beats Acurx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Vaxxinity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VAXX vs. The Competition

Export

Metric	Vaxxinity	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.77M	$953.36M	$6.66B	$12.19B
Dividend Yield	N/A	4.84%	2.68%	5.89%
P/E Ratio	-0.03	1.49	25.35	24.07
Price / Sales	N/A	118.21	588.85	125.28
Price / Cash	N/A	20.06	45.29	53.76
Price / Book	0.13	7.89	10.56	6.37
Net Income	-$56.93M	-$4.05M	$3.56B	$337.11M
7 Day Performance	N/A	-0.36%	1.00%	-0.93%
1 Month Performance	N/A	-0.02%	0.80%	0.65%
1 Year Performance	N/A	45.64%	31.01%	29.50%

Vaxxinity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VAXX Vaxxinity	N/A	$0.01 flat	N/A	+4,900.0%	$1.77M	N/A	N/A	90
NXTC NextCure	2.3239 of 5 stars	$2.02 -8.2%	$23.00 +1,038.6%	-68.3%	$7.29M	N/A	N/A	90	Positive News
ERNA Ernexa Therapeutics	3.1078 of 5 stars	$6.20 +5.3%	$30.00 +383.9%	-87.3%	$7.23M	N/A	N/A	10	News Coverage Gap Up
TNFA TNF Pharmaceuticals	0.2482 of 5 stars	$3.86 -0.3%	N/A	-72.2%	$7.13M	N/A	N/A	6
CNSP CNS Pharmaceuticals	2.4124 of 5 stars	$4.70 +3.8%	$20.00 +325.5%	-54.2%	$6.86M	N/A	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VAXX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxxinity (VAXX) Competitors

VAXX vs. NXTC, ERNA, TNFA, CNSP, and ACXP

How does Vaxxinity compare to NextCure?

Summary

How does Vaxxinity compare to Ernexa Therapeutics?

Summary

How does Vaxxinity compare to TNF Pharmaceuticals?

Summary

How does Vaxxinity compare to CNS Pharmaceuticals?

Summary

How does Vaxxinity compare to Acurx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VAXX vs. The Competition

Vaxxinity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxxinity (VAXX) Competitors

VAXX vs. NXTC, ERNA, TNFA, CNSP, and ACXP

How does Vaxxinity compare to NextCure?

Which has stronger valuation & earnings, VAXX or NXTC?

Does the media refer more to VAXX or NXTC?

Do institutionals & insiders hold more shares of VAXX or NXTC?

Which has more risk and volatility, VAXX or NXTC?

Do analysts prefer VAXX or NXTC?

Is VAXX or NXTC more profitable?

Summary

How does Vaxxinity compare to Ernexa Therapeutics?

Is VAXX or ERNA more profitable?

Do institutionals & insiders hold more shares of VAXX or ERNA?

Do analysts recommend VAXX or ERNA?

Does the media prefer VAXX or ERNA?

Which has higher valuation & earnings, VAXX or ERNA?

Which has more volatility and risk, VAXX or ERNA?

Summary

How does Vaxxinity compare to TNF Pharmaceuticals?

Which has more volatility and risk, TNFA or VAXX?

Is TNFA or VAXX more profitable?

Which has higher valuation and earnings, TNFA or VAXX?

Do analysts rate TNFA or VAXX?

Does the media refer more to TNFA or VAXX?

Do insiders & institutionals hold more shares of TNFA or VAXX?

Summary

How does Vaxxinity compare to CNS Pharmaceuticals?

Is VAXX or CNSP more profitable?

Which has more volatility and risk, VAXX or CNSP?

Do insiders and institutionals have more ownership in VAXX or CNSP?

Do analysts recommend VAXX or CNSP?

Which has better earnings & valuation, VAXX or CNSP?

Does the media favor VAXX or CNSP?

Summary

How does Vaxxinity compare to Acurx Pharmaceuticals?

Which has more volatility and risk, ACXP or VAXX?

Do insiders and institutionals have more ownership in ACXP or VAXX?

Does the media favor ACXP or VAXX?

Is ACXP or VAXX more profitable?

Do analysts recommend ACXP or VAXX?

Which has higher earnings and valuation, ACXP or VAXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VAXX vs. The Competition

Vaxxinity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools